1457 related articles for article (PubMed ID: 23448451)
41. Cardiac manifestations in Fabry disease.
Linhart A; Lubanda JC; Palecek T; Bultas J; Karetová D; Ledvinová J; Elleder M; Aschermann M
J Inherit Metab Dis; 2001; 24 Suppl 2():75-83; discussion 65. PubMed ID: 11758683
[TBL] [Abstract][Full Text] [Related]
42. Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy.
Lee MH; Choi EN; Jeon YJ; Jung SC
Int J Mol Med; 2012 Dec; 30(6):1275-80. PubMed ID: 23007467
[TBL] [Abstract][Full Text] [Related]
43. Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy.
Yogasundaram H; Kim D; Oudit O; Thompson RB; Weidemann F; Oudit GY
Can J Cardiol; 2017 Jul; 33(7):883-897. PubMed ID: 28668140
[TBL] [Abstract][Full Text] [Related]
44. Treatment of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Daidone M; Miceli S; Pinto A
Curr Pharm Des; 2020; 26(40):5089-5099. PubMed ID: 32183665
[TBL] [Abstract][Full Text] [Related]
45. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
[TBL] [Abstract][Full Text] [Related]
46. [Pathophysiological aspects of brain structural disturbances in patients with Fabry disease: literature review].
Nill M; Müller MJ; Beck M; Stoeter P; Fellgiebel A
Fortschr Neurol Psychiatr; 2006 Dec; 74(12):687-95. PubMed ID: 17167727
[TBL] [Abstract][Full Text] [Related]
47. Fabry disease: genetics, pathology, and treatment.
Bernardes TP; Foresto RD; Kirsztajn GM
Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s10-s16. PubMed ID: 31939530
[TBL] [Abstract][Full Text] [Related]
48. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome.
Nance CS; Klein CJ; Banikazemi M; Dikman SH; Phelps RG; McArthur JC; Rodriguez M; Desnick RJ
Arch Neurol; 2006 Mar; 63(3):453-7. PubMed ID: 16533976
[TBL] [Abstract][Full Text] [Related]
49. Diagnosis and Screening of Patients with Fabry Disease.
Vardarli I; Rischpler C; Herrmann K; Weidemann F
Ther Clin Risk Manag; 2020; 16():551-558. PubMed ID: 32606714
[TBL] [Abstract][Full Text] [Related]
50. Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.
Laffer B; Lenders M; Ehlers-Jeske E; Heidenreich K; Brand E; Köhl J
Front Immunol; 2024; 15():1307558. PubMed ID: 38304433
[TBL] [Abstract][Full Text] [Related]
51. Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy.
Shimohata H; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
CEN Case Rep; 2020 Aug; 9(3):237-242. PubMed ID: 32189245
[TBL] [Abstract][Full Text] [Related]
52. Clinic-Pathologic Features and Renal Outcome of Fabry Disease: Data from a Chinese Cohort.
Zhang D; Zhang J; Liang S; Wang J; Liu Z
Am J Nephrol; 2018; 48(2):137-146. PubMed ID: 30110672
[TBL] [Abstract][Full Text] [Related]
53. Fabry disease: a review.
Masson C; Cissé I; Simon V; Insalaco P; Audran M
Joint Bone Spine; 2004 Sep; 71(5):381-3. PubMed ID: 15474388
[TBL] [Abstract][Full Text] [Related]
54. Cardiac manifestations in patients with classical or cardiac subtype of Fabry disease.
Wang WT; Sung SH; Liao JN; Hsu TR; Niu DM; Yu WC
J Chin Med Assoc; 2020 Sep; 83(9):825-829. PubMed ID: 32649415
[TBL] [Abstract][Full Text] [Related]
55. Fabry disease.
Yuasa T; Takenaka T; Higuchi K; Uchiyama N; Horizoe Y; Cyaen H; Mizukami N; Takasaki K; Kisanuki A; Miyata M; Ohishi M
J Echocardiogr; 2017 Dec; 15(4):151-157. PubMed ID: 28674962
[TBL] [Abstract][Full Text] [Related]
56. Renal involvement in paediatric Fabry disease.
Sestito S; Falvo F; Sallemi A; Petrisano M; Scuderi MG; Tarsitano F; D'Angelo G; Betta P; Roppa K; Parisi F; Pensabene L; Fede C; Chimenz R; Concolino D
J Biol Regul Homeost Agents; 2019; 33(5 Suppl. 1):59-63. Special Issue: Focus on Pediatric Nephrology. PubMed ID: 31630715
[TBL] [Abstract][Full Text] [Related]
57. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.
Terryn W; Cochat P; Froissart R; Ortiz A; Pirson Y; Poppe B; Serra A; Van Biesen W; Vanholder R; Wanner C
Nephrol Dial Transplant; 2013 Mar; 28(3):505-17. PubMed ID: 23234755
[TBL] [Abstract][Full Text] [Related]
58. [Evaluation of patients with Fabry disease in Argentina].
AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
[TBL] [Abstract][Full Text] [Related]
59. Anderson-Fabry disease in heart failure.
Akhtar MM; Elliott PM
Biophys Rev; 2018 Aug; 10(4):1107-1119. PubMed ID: 29909504
[TBL] [Abstract][Full Text] [Related]
60. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
